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Background: Medication nonadherence is a major cause of hospitalization in patients with heart 
failure (HF), which contributes enormously to health care costs. We previously found, using 
the World Health Organization adherence dimensions, that condition and patient level factors 
predicted nonadherence in HF. In this study, we assessed a wider variety of condition and patient 
factors and interactions to improve our ability to identify those at risk for hospitalization. 
Materials and methods: Medication adherence was measured electronically over the course 
of 6 months, using the Medication Event Monitoring System (MEMS). A total of 242 HF 
patients completed the study, and usable MEMS data were available for 218 (90.1%). Partici-
pants were primarily white (68.3%), male (64.2%), and retired (44.5%). Education ranged from 
8–29 years (mean, 14.0 years; standard deviation, 2.9 years). Ages ranged from 30–89 years (mean, 
62.8 years; standard deviation, 11.6 years). Analyses used adaptive methods based on heuristic 
searches controlled by cross-validation scores. First, individual patient adherence patterns over 
time were used to categorize patients in poor versus better adherence types. Then, risk factors for 
poor adherence were identified. Finally, an effective model for predicting poor adherence was 
identified based on identified risk factors and possible pairwise interactions between them. 
Results: A total of 63 (28.9%) patients had poor adherence. Three interaction risk factors for 
poor adherence were identified: a higher number of comorbid conditions with a higher total 
number of daily medicines, older age with poorer global sleep quality, and fewer months since 
diagnosis of HF with poorer global sleep quality. Patients had between zero and three risk fac-
tors. The odds for poor adherence increased by 2.6 times with a unit increase in the number of 
risk factors (odds ratio, 2.62; 95% confidence interval, 1.78–3.86; P0.001).
Conclusion: Newly diagnosed, older HF patients with comorbid conditions, polypharmacy, 
and poor sleep are at risk for poor medication adherence. Interventions addressing these specific 
barriers are needed.
Keywords: heart failure, medication adherence, multiple chronic conditions, risk factors, 
self-care, sleep quality
Introduction
Heart failure (HF) affects more than five million adults (12% of older adults) in the 
United States.1 For patients, the symptoms of fatigue, shortness of breath, depression, 
poor memory, and impaired sleep make HF burdensome.2 Symptoms drive hospital-
ization: one in four HF patients is readmitted to a hospital within 30 days of hospital 
discharge, and almost half are readmitted within 6 months.3 These hospitalizations are 
the primary contributor to the staggering medical cost of HF: $30.7 billion annually.4 
This cost is projected to increase more than twofold by 2030, making HF the most 
expensive condition billed to Medicare.5
A variety of reasons for HF hospitalization have been described, but as noted by 
Desai and Stevenson6 a robust and actionable model of risk factors for hospitaliza-
tion is needed. In a prior study, we developed an effective model of risk factors for 
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 hospitalization and demonstrated that medication nonadher-
ence was the best predictor of hospitalization in a sample of HF 
patients, after considering numerous demographic, support, 
clinical, symptom, cognitive, and self-care factors.7 This result 
is not surprising, in that most authors have found medication 
nonadherence rates between 40% and 60% in patients with 
HF.8 At this point, the urgent need is to identify modifiable 
factors associated with medication nonadherence.
In the prior study, we used recently developed adaptive 
modeling methods to analyze objectively measured medica-
tion adherence as collected prospectively, using the Medica-
tion Event Monitoring System (MEMS®; AARDEX Group 
Ltd, Sion, Switzerland), which records the date and time 
of each opening of the MEMS device, and presumably the 
taking of a dose of the associated medication. We identified 
individual patient medication adherence patterns over time 
and clustered these patterns into adherence types.7 These 
adherence types were used to identify the two categories 
of poor versus (vs) better adherence, an approach that is 
distinctly more sensitive than categorizations of adherence 
based on percentage prescribed doses taken (eg, 80% 
vs 80%). This nuanced approach contributed significantly 
to the predictive capability of the model for hospitalization, 
which had excellent discrimination characteristics.7 In this 
article, we build on previously identified individual patient 
adherence patterns and types and describe risk factors for 
poor adherence. 
This is a second article exploring predictors of medica-
tion adherence in HF patients. In the first article, we used 
the World Health Organization9 dimensions of adherence 
(socioeconomic, condition, therapy, patient, and health care 
system) to focus our analyses.10 These dimensions reflect the 
types of variables found to predict treatment adherence in 
various populations.11,12 In our first study of HF patients, we 
determined that patient and condition characteristics contrib-
uted most to a steep decline in medication adherence. Patients 
with lapses in attention (odds ratio [OR], 2.65; P=0.023), 
excessive daytime sleepiness (OR, 2.51; P=0.037), and two 
or more medication dosing intervals per day (OR, 2.59; 
P=0.016) were more likely to have a steep decline in adher-
ence over time than to have persistent adherence.10 However, 
as only a select group of possible predictors was tested in 
that study and no interactions were explored, in this current 
study, we build on our earlier work by assessing a wider 
variety of available conditions and patient-level risk factors 
for poor adherence. The purpose of this work is to identify 
risk factors associated with medication adherence problems 
in HF patients, with the ultimate goal of  identifying and 
implementing interventions that address important barriers to 
adherence, and so reduce the chance of hospitalization. This 
purpose will be addressed in three steps: identify individual 
risk factors for poor adherence, identify a multiple risk fac-
tors model for poor adherence, and identify a multiple risk 
factors and interactions model for poor adherence.
Materials and methods
This was a secondary analysis of adherence data from 
a prospective cohort study of a consecutive sample of 
280 adults with a confirmed diagnosis of HF enrolled from 
three outpatient sites in the northeastern United States; 242 
(86.4%) of these patients completed the 6-month study.13 
Institutional review board approval was obtained at the 
University of Pennsylvania, the participating sites where we 
enrolled participants, and the University of North Carolina 
at Chapel Hill, and all participants gave informed consent. 
The primary objective of the parent study was to clarify the 
extent to which excessive daytime sleepiness influences HF 
self-care and clinical outcomes and the mechanism of the 
effect. Study methods have been described previously.13 
Participants were preferentially sampled for variability 
in daytime sleepiness and cognition. Patients with severe 
depression, dementia (Telephone Interview for Cognitive 
Status [TICS] scores 2414), renal failure requiring dialysis, 
terminal illness, or history of serious drug or alcohol abuse 
within the past year were excluded. Because the parent study 
focused on sleepiness, patients with night-shift responsibili-
ties were excluded. Study participants were followed-up for 
6 months, with home visits at baseline, 3, and 6 months, 
where data were collected by research assistants. A list of all 
medications taken, including over-the-counter and as-needed 
medications, was made on the basis of visual assessment by 
the research assistant during the home visit. As almost half of 
all HF patients are readmitted to a hospital within 6 months, 
a 6-month interval was deemed adequate for follow-up.3,6,15 
Nurses abstracted clinical information, including comorbid 
conditions, from medical records. All data were collected 
between 2007 and 2009.
Measures
Medication adherence was assessed using MEMS, a valid 
method of measuring medication-taking behavior.16,17 Meth-
ods used to collect these MEMS data have been described in 
detail elsewhere,10 but MEMS data were collected for a single 
selected medication scheduled to be taken one to three times 
daily. Our preference was that the MEMS be used with a medi-
cation taken in multiple daily doses, but sometimes negotiation 
was necessary when the medication to be used in the device 
was chosen. Only one medication was monitored, a practice 
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that has been shown to be adequate because a single drug 
can be used to illustrate medication-taking patterns.18,19 Most 
patients (56.7%) put their beta-blocker in the device, but 15.2% 
put an angiotensin-converting-enzyme inhibitor in it. Putting a 
diuretic in the device was strongly discouraged, and only seven 
patients (3.2%) put their diuretic in the MEMS. MEMS data 
were downloaded for each patient at 3 and 6 months and were 
cleaned based on patient diaries, with clarification provided by 
telephone as needed. Specifically, patients were asked to note 
in their research diary whether something unusual happened 
that gave misleading data. An example would be that, after 
refilling a prescription, the device was opened an extra time 
that day to fill it with medicine. These types of incidents were 
captured in the diary and adjusted in the raw data. Participants 
were fully informed about the MEMS device, but telling 
patients that their medication dosing will be monitored is not 
sufficient to change behavior significantly.20
The World Health Organization9 dimensions of 
adherence (socioeconomic, condition, therapy, patient, 
and health care system) were used to focus the choice 
of additional indicators of the most promising dimen-
sions and patient-related and condition-related factors. 
Patient-related variables were grouped into the categories 
of demographic (Table 1) and social support (Table 2). 
Condition-related factors were classified as clinical (Table 3), 
self-care (Table 4), symptom (Table 5), and cognition 
(Table 6) variables. Only baseline values for these variables 
were used in analyses. A variety of standard scales were 
considered; these scales and their psychometric properties 
are summarized in Table 7. Cognition was measured by a 
battery of neuropsychological tests, including the Digit 
Symbol Substitution Test, the Letter Number Sequencing 
subtest, the Probed Memory Recall Task, and the Trail 
Making Test: A and B.21 The non-scale-based variables of 
Tables 1–6 are self-explanatory. 
Some variables were derived from investigator-generated 
lists such as the Compensatory Activities Score. Participants 
were presented with a list of behaviors used by patients 
(eg, lists) and support persons (eg, reminders) to compensate 
for memory problems. The number endorsed was used to 
compute the Compensatory Activities Score. Fatigue was 
measured as the sum of two items from the Kansas City 
Cardiomyopathy Questionnaire.22 These items ask how many 
times fatigue has limited the ability to do activities and how 
bothersome fatigue has been. Each item is scored 1 to 7. 
Fatigue scores ranging from 2 to 14 were reversed so that 
higher scores indicate more fatigue. The alpha coefficient of 
the fatigue measure was 0.90. 
Data analysis
In our prior study using adaptive methods23 to model the 
effect of medication adherence on hospitalization for the 
Table 1 summary statistics for available demographic variables
Variable and observed range n (%)* Mean (SD; n)*
employment status
retired 97 (44.5)
Unemployed or disabled 62 (28.4)
employed (full or part time) 59 (27.1)
sex
Male 140 (64.2)
Female 78 (35.8)
income
Do not have enough 35 (16.1)
have enough or more 183 (83.9)
insurance
government or none 122 (56.0)
commercial or health maintenance organization 96 (44.0)
race
nonwhite 69 (31.7)
White 149 (68.3)
Age
30–89 62.8 (11.6; 218)
AnArT score
0–49 31.0 (11.2; 218)
Years of education
8–29 14.0 (2.9; 218)
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviations: sD, standard deviation; AnArT, American national Adult reading Test.
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same adherence data, we identified seven adherence types.7 
First, individual adherence patterns were generated for each 
patient, consisting of possibly nonlinear mean adherence and 
adherence variability curves over time. These adherence pat-
terns were adjusted for prescribed medication rates so that the 
ideal adherence pattern had mean adherence 1 at each time, 
with no variability. Then, these patterns were  clustered into 
seven adherence types consisting of patients with similar 
adherence patterns. The best combination of these seven 
adherence types for predicting hospitalization was the 
dichotomous adherence type of poor adherence (ie, with very 
low adherence some time during study participation) versus 
better adherence (ie, primarily moderate or better levels of 
adherence throughout study participation). This dichotomous 
poor adherence type is modeled in reported analyses.
In this study, adaptive methods23 were used to identify risk 
factors, individually and in combination, for poor adherence, 
as previously identified from MEMS adherence data.7 Adap-
tive methods have been used previously for modeling adher-
ence for HIV-positive patients,24,25 hypertensive patients,26 
and HF patients.7 These methods use k-fold likelihood 
cross-validation (LCV) scores for model selection. The data 
are randomly partitioned into k distinct subsets, called folds. 
Likelihoods are computed for each fold, using parameter 
estimates for the data in the other folds. These deleted fold 
likelihoods are then combined into a LCV score, with larger 
scores indicating better models for the data. LCV scores 
provide for an objective evaluation of models, independent 
of the size of estimated parameter values (such as ORs 
for logistic regression models) and of P-values. Reported 
analyses used 10-fold LCV scores computed from likelihoods 
for logistic regression models.
The model with the largest LCV score is not always the 
best choice. A less-complex model may be preferable if the 
reduction in the LCV score is insubstantial (nonsignificant 
or indistinct). LCV ratio tests, analogous to likelihood ratio 
tests, can be used to make such assessments. Although these 
are χ2-based tests, they are expressed in terms of a cutoff for 
a substantial (significant or distinct) percentage decrease in 
the LCV score. A model generating a percentage decrease 
in the LCV score greater than this cutoff is substantially 
improved on by the model with the larger LCV score. 
Table 2 summary statistics for available social support variables
Variable and observed range n (%)* Mean (SD; n)*
living alone
Yes 48 (22.0)
no 170 (78.0)
Marital status
single, divorced, separated, or widowed 88 (40.4)
Married or partnered 130 (59.6)
Quality of support
satisfactory to good 75 (34.4)
Very good 143 (65.6)
MsPss score
14–84 72.9 (11.3; 210)
Note: *Out of 218 patients with Medication event Monitoring system data.
Abbreviations: sD, standard deviation; MsPss, Multidimensional scale of Perceived social support.
Table 3 summary statistics for available clinical variables
Variable and observed range n (%)* Mean (SD; n)*
exercise
none 36 (16.5)
some 182 (83.5)
Body mass index, kg/m2
15–67 30.8 (7.9; 218)
Blood urea nitrogen
6–97 24.8 (13.8; 216)
charlson total
1–11 2.7 (1.8; 218)
comorbidities
0–9 3.0 (2.1; 218)
creatinine
0.5–3.4 1.3 (0.5; 215)
Diastolic blood pressure
45–103 68.9 (110.8; 216)
ejection fraction
5–80 35.8 (17.4; 217)
hemoglobin
8.1–18.4 13.1 (1.8; 209)
Months since heart failure diagnosis
0–508 76.2 (75.5; 203)
Pulse
42–100 69.8 (11.5; 218)
serum sodium
131–146 139.1 (2.9; 213)
systolic blood pressure
80–176 116.0 (17.5; 217)
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviation: sD, standard deviation.
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In contrast, a model generating a percentage decrease in the 
LCV score less than or equal to the cutoff is a competitive 
alternative to the model with the larger LCV score. If the 
model with the lower score is also less complex, then it is a 
parsimonious, competitive alternative and, thus, preferable. 
For example, if the constant model for predicting adherence 
generates an insubstantial percentage decrease in the LCV 
score in comparison with the model based on a specific risk 
factor, then the constant model is preferable, and so the risk 
factor is not a substantive predictor of adherence. The cutoff 
changes with the sample size. 
Patients with poor adherence were characterized by 
identifying risk factors for poor adherence from among the 
variables of Tables 1–6. Categorical variables were used as 
reported. For each continuous and ordinal variable, observed 
values were categorized into lower versus higher values, 
using each observed value as a cutoff. The cutoff with the 
best (largest) LCV score was used to determine the associated 
Table 4 summary statistics for available self-care variables
Variable and observed range n (%)* Mean (SD; n)*
Prescribed rate for medication controlled by MeMs
2–3 133 (61.0)
1 85 (39.0)
DhFKs score
7–15 11.7 (1.6; 211)
SCHFI self-care confidence
42–100 75.7 (14.4; 218)
schFi self-care maintenance
32–92 66.8 (11.6; 215)
schFi self-care management
29–100 66.1 (18.6; 94)**
Total medications
1–25 9.9 (3.9; 218)
Notes: *Out of patients with available MeMs data; **patients with missing schFi self-care management values were those with no symptoms to manage.
Abbreviations: sD, standard deviation; MeMs, Medication event Monitoring system; DhFKs, Dutch heart Failure Knowledge score; schFi, self-care of heart 
Failure index.
Table 5 summary statistics for available symptom variables
Variable and observed range n (%)* Mean (SD; n)*
general health perception
Poor 24 (11.0)
Fair to excellent 194 (89.0)
health compared with a year ago
Poor 17 (7.8)
Fair to excellent 201 (92.2)
Trouble breathing or ankle swelling within past month
Yes 94 (43.1)
no 124 (56.9)
nYhA class
iV 41 (18.8)
i–iii 177 (81.2)
Fatigue
2–13 6.4 (3.0; 218)
sss score
1–6 2.2 (1.2; 218)
ess score
0–23 6.7 (4.5; 218)
PsQi global sleep score
0–19 7.1 (4.0; 218)
PhQ total
0–18 4.4 (3.6; 218)
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviations: sD, standard deviation; nYhA, new York heart Association; sss, stanford sleepiness scale; ess, epworth sleepiness scale; PsQi, Pittsburgh sleep Quality 
index; PhQ, Patient health Questionnaire.
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potential risk factor. The risk factor category corresponded 
to the range of values generating an OR greater than 1 for 
poor adherence. When a predictor had missing values, those 
observations were conservatively assigned to the non-risk 
factor category. In this way, all patients having an identi-
fied risk factor had non-missing values for the associated 
predictor. Cutoffs with less than 10% of the observations in 
either the lower or higher categories were excluded to avoid 
sparse cases. 
Categorizing continuous/ordinal variables into dichoto-
mous risk factors has the advantage of allowing for missing 
values without loss of data and of having a practical clini-
cal interpretation. However, the disadvantage is possible 
loss of information. Whether substantial information has 
been lost or not can be assessed by comparing LCV scores 
for a dichotomous risk factor model with the model based 
on the associated continuous/ordinal variable. This is only 
possible if that variable has no missing values, as LCV 
scores are only comparable when based on the same set 
of data.
Bivariate models were generated for all potential risk 
factors. Then a multiple risk factors model was generated, 
using the adaptive modeling process of Knafl et al23 consider-
ing only the risk factors with significant (P0.05) bivariate 
effects. This adaptive modeling process has been described 
elsewhere.7,26 In this case, the process first adds risk factors 
systematically to the model and then contracts the expanded 
model to remove extraneous risk factors, if any, using a LCV 
ratio test to decide when to stop the contraction. 
Next, an adaptive model was generated with this same 
process, but considering the same set of risk factors as well 
as possible pairwise interactions between any two of them 
to obtain an assessment of the effect of interactions between 
risk factors. Pairwise interactions holding for less than 10% 
of the observations were excluded to avoid sparse cases. 
Finally, this latter model was used to compute a risk index 
for poor adherence for patients as the count of that model’s 
risk factors and risk factor interactions.
Results
sample
Usable MEMS data were available for 218 (90.1%) of the 
242 parent study subjects who completed that study. Sum-
mary statistics for the patients with usable MEMS data are 
presented in Tables 1–6 for available variables within the 
six categories described earlier. For example, patients were 
primarily white (68.3%), male (64.2%), and retired (44.5%). 
Education ranged from 8–29 years, with a mean of 14.0 years 
(standard deviation, 2.9 years), whereas ages ranged from 
30–89 years, with a mean of 62.8 years (standard deviation, 
11.6 years). A total of 63 (28.9%) of the patients with usable 
MEMS data had poor medication adherence. 
risk factors for poor adherence
Table 8 presents results for characterizing poor adherence, 
considering the variables of Tables 1–6, one at a time. Indi-
vidual risk factor analyses identified 12 significant (P0.05) 
individual risk factors for poor adherence, including one 
demographic, zero social support, three clinical, one self-
care, four symptom, and three cognition risk factors. The 
cutoff for a substantial percentage decrease in LCV scores 
for these analyses is 0.88%. The percentage decrease for the 
constant model exceeds this cutoff for only two (16.7%) of 
the twelve variables (LCV scores not reported), indicating 
that LCV ratio tests are more conservative than tests for 
zero coefficients, and thus are similar in effect to multiple 
comparisons procedures. 
There are five continuous/ordinal variables with no miss-
ing values generating individual risk factors in Table 8. For 
two of these variables (number of comorbidities and TICS 
score), the LCV scores were better for the individual linear 
models, but with insubstantial percentage decreases for the 
associated individual risk factor model (0.55357 vs 0.55543 
and 0.54778 vs 0.54826, with percentage decreases of 0.33% 
and 0.09%, respectively). For two other of these variables 
Table 6 summary statistics for available cognition variables
Variable and observed range Mean (SD; n)*
cAs 
0–23 9.4 (4.4; 218)
DssT score
11–96 54.4 (16.7; 217)
lns score
1–20 8.9 (3.4; 214)
PMr score
0–4 2.1 (1.2; 217)
PVT lapses
0–79 7.8 (12.4; 214)
Tics score
26–40 33.8 (2.9; 218)
TMTA score
14–120 41.5 (17.3; 218)
TMTB score
8–300 105.3 (53.3; 217)
Dimensions cognitively impaired
0–5 1.6 (1.0; 218)
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviations: sD, standard deviation; cAs, compensatory Activities score; 
DssT, Digit symbol substitution Test; lns, letter number sequencing; PMr, Probed 
Memory recall; PVT, Psychomotor Vigilance Task; Tics, Telephone interview for 
cognitive status; TMTA, Trail Making Test: A; TMTB, Trail Making Test: B.
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(age and total medications), the LCV scores were worse for 
the individual linear models, but with insubstantial percent-
age decreases compared with the associated individual risk 
factor model (0.54820 vs 0.55160 and 0.54622 vs 0.54894, 
with percentage decreases 0.62% and 0.50%, respectively). 
For the fifth variable (Patient Health Questionnaire27 total 
score), the LCV score was worse for the individual linear 
model and with a substantial percentage decrease compared 
Table 7 summary of each standard scale used
Scale name Description Psychometric properties
American national Adult 
reading Test (AnArT)53,54
Measure of premorbid, crystalized intellect. A list of  
50 phonetically irregular words (eg, aisle) is read aloud. 
The number of words pronounced correctly is used  
as the score.
reliabilityby cronbach’s alpha was 0.93. Validity was 
demonstrated by comparing with the Wechsler Adult 
intelligence scale-revised (WAis-r) vocabulary test; 
coefficient was 0.75.
Multidimensional scale of 
Perceived social support 
(MsPss)55,56
A 12-item measure assessing social support from 
family, friends, and a significant other. Responses range 
from 1 (very strongly disagree) to 7 (very strongly 
agree), with higher scores indicating more perceived 
support.
Reliability coefficients range from 0.85–0.91. Factorial 
validity has been confirmed repeatedly.
charlson comorbidity index57 seventeen broad categories of conditions scored 
with 1–6 points. scores range from 0–34 and can be 
classified as low, moderate, and high comorbidity.
established validity for predicting mortality, 
complications, health care resource use, length of 
hospital stay, discharge disposition, and cost.
Dutch heart Failure 
Knowledge score58
Fifteen items measuring general knowledge of hF 
and knowledge of hF treatments, hF symptoms, and 
symptom recognition.
items based on established patient education 
guidelines of the netherlands heart Foundation, 
which mirror those of the American heart 
Association.
self-care of heart Failure 
index (schFi V6.2)59
Twenty-two items, measured using a four-point self-
report response format, which form three scales: self-
care maintenance, management, and confidence.
internal consistency tested by factor score 
determinacy, coefficients all 0.70. Moderate to high 
correlations over time in test–retest reliability testing. 
construct validity has been demonstrated. The schFi 
is sensitive to subtle behavioral changes in a variety of 
hF samples.
epworth sleepiness scale 
(ess)60
A measure of global or typical sleepiness. respondents 
rate the likelihood of falling asleep in eight soporific 
situations using a four-point likert scale ranging from 
never dozing (0) to high chance of dozing (3).
Test–retest reliability (r=0.82) and internal 
consistency (α=0.88) have been established. single 
factor structure. ESS correlates significantly with the 
frequency of apneas and has a sensitivity of 93.5% and 
a specificity of 100% for distinguishing pathological 
from normal sleepiness.
stanford sleepiness scale61 The stanford sleepiness scale provides a rating of 
sleepiness at a particular moment in time. current 
degree of sleepiness is rated 1 (vital, alert, or wide-
awake) to 7 (feeling that sleep onset is soon).
sensitive to both sleep deprivation and time of 
day. reliability tested as the correlation between 
alternative forms was adequate (0.88).
Patient health Questionnaire 
(PhQ-9)27
The PhQ-9 is a measure of depression. scores of 5, 
10, 15, and 20 represent mild, moderate, moderately 
severe, and severe depression, respectively.
reliable and valid in numerous populations including 
hF.
Pittsburgh sleep Quality index 
(PsQi)62
A self-report measure of the perception of habitual 
sleep quality measuring seven domains for the prior 
month: 1) sleep quality; 2) latency; 3) duration;  
4) habitual sleep efficiency; 5) use of sleep medications; 
6) disturbance; and 7) daytime dysfunction. A global 
score (0–21 points) is obtained by summing scale 
domain scores. higher scores indicate poorer global 
sleep quality.
internal consistency reliability is in the range of  
0.77–0.83. in test–retest reliability testing, scores 
were not significantly different. PSQI scores have been 
validated by comparison with polysomnography and 
shown to discriminate among known groups.
Psychomotor Vigilance Test 
(PVT)63
Measure of simple attention. subjects press a button 
in response to a series of red digits “000” in an 
automated light-emitting diode counter window of a 
small, portable device. signals are presented at random 
intervals over a 10-minute period. Metrics involving 
response speed and lapses are the best primary 
outcomes for the 10-min PVT.
highly sensitive measure of sleep deprivation.
Abbreviation: hF, heart failure.
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with the associated individual risk factor model (0.54308 
vs 0.54857, with percentage decrease 1.00%). These results 
indicate that, in this case, consideration of dichotomous risk 
factors does not result in loss of predictive capability over 
associated linear models. Further, sometimes dichotomous 
factors even provide distinct improvements in predictive 
capability.
The adaptive multiple risk factors model, generated con-
sidering the twelve significant risk factors of Table 8, had 
three risk factors: higher Trail Making Test: B, a measure 
of complex attention (P=0.002; OR, 3.36; 95% confidence 
interval [CI], 1.56–7.25); higher number of comorbid condi-
tions (P=0.025; OR, 2.04; 95% CI, 1.09–7.25); and lower 
HF duration (P=0.007; OR, 2.61; 95% CI, 1.30–5.22). The 
LCV score was 0.56824. In contrast, the best individual risk 
factor model based on a higher Trail Making Test: B score 
had an LCV score of 0.55545, with a substantial percentage 
decrease of 2.25%, indicating that the multiple risk factors 
model substantially improved on each of the individual risk 
factor models. 
The adaptive modeling process is based on LCV scores, 
so individual risk factors with large ORs need not be included 
in the adaptively generated multiple risk factor model, 
unless those risk factors also generate large LCV scores. For 
example, the risk factor based on a larger Pittsburgh Sleep 
Quality Index global sleep score generated the largest OR 
of 4.78 in Table 8. However, it had the fourth largest LCV 
score among individual risk factors (scores not reported in 
Table 8) and was not included in the adaptively generated 
multiple risk model. In contrast, the risk factor based on a 
larger Trail Making Test: B score had the second largest OR 
of 3.51 in Table 8. However, it also had the largest LCV score 
among individual risk factor models and was included in the 
adaptively generated multiple risk factor model. 
The adaptive model also considering pairwise risk factor 
interactions is described in Table 9. This model included three 
risk factor interactions (and no noninteraction risk factors): 
a higher number of comorbid conditions with a higher total 
number of medications, older age with poorer global sleep 
quality, and fewer months since diagnosis of heart failure 
(ie, less experience with the illness) with poorer global sleep 
quality. The c-index (also called the c-statistic; the same as 
the area under the receiver-operating characteristics curve) 
was 0.72, which is considered acceptable discrimination.28 
The LCV score for this model was 0.57665. The noninter-
action multiple risk factors model generated a substantial 
percentage decrease in the LCV score of 1.46%, indicating 
that consideration of interactions provided a substantial 
improvement over only using noninteraction risk factors for 
predicting poor adherence.
To assess the possibility of collinearity between these 
three interactions, we computed logistic regression models 
Table 8 Significant individual risk factor models of poor versus better adherence
Variable Factor n (%)* P-value OR 95% CI
Demographics
Age, years 61 vs 61 132 (60.6) 0.018 2.17 1.15–4.12
social support
–
clinical
comorbidities 4 vs 4 87 (39.9) 0.008 2.26 1.24–4.10
Months since heart failure 21 vs 21 or missing 50 (22.9) 0.008 2.43 1.26–4.71
Diastolic blood pressure 82 vs 82 or missing 22 (10.1) 0.026 2.77 1.13–6.77
self-care
Total medications 9 vs 9 132 (60.6) 0.038 1.95 1.04–3.68
symptoms
general health perception Poor vs fair to excellent 24 (11.0) 0.019 2.80 1.19–6.64
Trouble breathing or ankle  
swelling within past month
Yes vs no 94 (43.1) 0.040 1.86 1.03–3.35
PhQ total 10 vs 10 22 (10.1) 0.026 2.80 1.13–6.77
PsQi global sleep score 3 vs 3 or missing 195 (89.4) 0.039 4.78 1.09–21.0
cognition
DssT score 42 vs 42 or missing 55 (25.2) 0.016 2.21 1.16–4.21
Tics score 30 vs 30 36 (16.5) 0.027 2.30 1.10–4.80
TMTB score 148 vs 148 or missing 36 (16.5) 0.001 3.51 1.68–7.33
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviations: OR, odds ratio; CI, confidence interval; PHQ, Patient Health Questionnaire; PSQI, Pittsburgh Sleep Quality Index; DSST, Digit Symbol Substitution Test; 
Tics, Telephone interview for cognitive status; TMTB, Trail Making Test: B; vs, versus.
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predicting each of these three dichotomous interactions as a 
function of the other two. The largest Nagelkerke R2 value 
for these models was 4.5%, indicating that collinearity was 
not a problem for the risk factor interactions model.
Patients had zero to three of the three interaction risk 
factors, with 69 (31.7%) patients having none of the interac-
tion risk factors, 78 (35.8%) patients having one, 63 (28.9%) 
patients having two, and eight (3.7%) patients having three 
factors. For patients with poor adherence, percentages 
increased from 10.1% to 26.9%, 47.6%, and 62.5% of the 
69, 78, 63, and eight patients with zero to three interaction 
risk factors, respectively. The risk index model based on the 
number of risk factor interactions as the only predictor of 
poor adherence had an LCV score 0.57954. The risk factor 
interaction model was a parsimonious, competitive alterna-
tive with an insubstantial percentage decrease in the LCV 
score of 0.50%. The c-index for the risk index model was 
acceptable, at 0.71, and the estimated OR for a unit increase 
in the risk index variable was 2.62 (95% CI, 1.78–3.86; 
P0.001).
Discussion
In this study, we characterized poor medication adherence, 
as determined from our prior assessment of electronically 
monitored patient adherence.7 Our major finding was that 
three pairs of interaction risk factors successfully predicted 
having poor versus better medication adherence levels: a 
higher number of comorbid conditions with a higher total 
number of medications, older age with poorer global sleep 
quality, and fewer months since diagnosis of heart failure 
with poorer global sleep quality. The addition of even 
one interaction risk factor increased the odds of poor adher-
ence by about 2.6 times. Some of these risk factors are 
modifiable and provide direction for intervention.
These results differ in important ways from our prior 
analysis of predictors of MEMS-based adherence data.10 
First, in that analysis, using growth mixture modeling, we 
identified two distinct patterns, and 22% of HF patients 
were in the “steep decline” or poorest medication-adherence 
group. In the current analysis, when the seven distinct types, 
accounting for both means adherence and adherence vari-
ability over time, as identified earlier,7 were collapsed into 
two types, 28.9% were in the poor medication adherence 
type. Second, having focused the analysis of contributors to 
a steep decline in adherence on a select group of variables 
suggested by the World Health Organization model, we 
identified only three contributors: lapses in attention, exces-
sive daytime sleepiness, and two or more medication doses 
per day. Moreover, interactions were not considered. In this 
analysis, we tested more potential contributors in the prom-
ising dimensions of patient- and condition-related factors 
and assessed potential interactions. This approach revealed 
three specific pairs of interacting risk factors likely to 
increase the odds of medication nonadherence. Interestingly, 
the number of daily medication doses for the drug used in 
the MEMS device did not predict adherence, although this 
factor has been found repeatedly in other studies.29,30 Perhaps 
this was a result of considering adherence variability along 
with mean adherence, rather than just mean adherence, in 
forming adherence types. 
We found that a higher number of comorbid condi-
tions plus more medications taken daily or polypharmacy, 
conventionally defined as the chronic use of five or more 
medications,31 predicted poor medication adherence. These 
results are consistent with those of others who have found 
that more comorbid conditions and more pills taken each day 
predicted poor medication adherence.32 We found previously 
that HF patients with multiple comorbid conditions find that 
differentiating the symptoms of multiple conditions is one 
of the most challenging self-care skills.33 Having multiple 
conditions also decreases self-efficacy or confidence in one’s 
ability to perform specific self-care tasks such as medication 
Table 9 Multiple risk Factor interactions Model for poor versus better adherence
Description Interaction term 1 Interaction term 2 At risk group, 
n (%)*
P-value OR 95% CI
Variable Risk factor Variable Risk factor
higher number of comorbidities  
with higher total medications
comorbidities 4 vs 4 Total medications 9 vs 9 67 (30.7) 0.2 2.89 1.18–7.06
Older age with poorer global  
sleep quality
Age 61 vs 61 PsQi global  
sleep score
3 vs 3  
or missing
117 (53.7) 0.004 3.20 1.45–7.07
Fewer months since diagnosis of  
heart failure with poorer global  
sleep quality
Months since  
heart failure
21 vs 21  
or missing
PsQi global  
sleep score
3 vs 3  
or missing
44 (20.2) 0.006 2.82 1.35–5.85
Note: *Out of 218 patients with some Medication event Monitoring system data.
Abbreviations: OR, odds ratio; CI, confidence interval; PSQI, Pittsburgh Sleep Quality Index; vs, versus.
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taking.34 When intervention studies were examined in a sys-
tematic review, medication adherence increased most consis-
tently with behavioral interventions that reduced medication 
dosing demands,35 illustrating that polypharmacy adds a level 
of complexity to life with multiple chronic conditions that 
predisposes patients to poor medication adherence. In fact, 
the essence of medication reconciliation, a popular approach 
for patients with multiple chronic conditions, involves ana-
lyzing and resolving medication discrepancies and typically 
decreases the number of pills taken daily.36
Another pair of risk factors for medication nonadherence 
was the interaction of older age and poorer sleep quality. 
We are not the first investigators to identify older age as 
a factor in nonadherence.5,15,37 Poor sleep quality is also 
known to impair the ability to pay attention and make good 
decisions.38,39 However, the interaction of older age and 
poor sleep quality may be best explained by the compelling 
mechanistic explanation described by Neupert et al37 who 
examined how daily fluctuations in cognition and busyness 
are related to daily fluctuations in forgetting to take medica-
tions and whether these within-person relationships differed 
for younger and older adults. On days when the older adults in 
their study were relatively less busy, they were at lower risk 
for forgetting to take their medicines, but only if they were 
also performing well on the everyday cognition assessments. 
This observation is consistent with our findings that poor 
sleep quality contributes to forgetting to take medications.10,13 
Together these results reinforce the salience of daily routines 
and lifestyle factors such as sleep routines, as they influence 
memory in older adults.
Finally, patients with a shorter duration of HF or less 
experience with the diagnosis and poor sleep quality were 
at higher risk for nonadherence. Others have demonstrated 
previously that patients who are newly diagnosed with HF 
struggle with self-care.40,41 Dickson et al described a typology 
in which novices lacked experience and skill in caring for 
their HF diagnosis.42 Knowing that attention and decision-
making are impaired by poor sleep and that better decisions 
are made by people with illness experience, the interaction 
between shorter duration of HF and poor sleep quality in 
predicting nonadherence is not surprising.
Together, these results suggest that older age, multiple 
comorbid conditions, polypharmacy, lack of experience, and 
poor sleep quality put HF patients at risk for poor medica-
tion adherence. Fortunately, interventions addressing some 
of these predictors are available. Systematic evaluation and 
modification of the medication regimen (including over-the-
counter medicines) in all HF patients could address many of 
the problems caused by polypharmacy. Multidrug combina-
tions or “polypills” have been advocated as a solution to 
drug–drug interactions and poor treatment adherence.43 Lack 
of experience is best addressed with education and support. 
We found previously that about 2 months after being diag-
nosed with HF, patients improve in their abilities to adhere 
to the treatment program, detect symptoms, and make good 
decisions about those symptoms.41 Steering newly diagnosed 
patients toward a sustainable routine during that 2-month 
period may decrease problems with medication adherence. 
Surprisingly, interventions for poor sleep quality are the 
most challenging. For people with sleep apnea, continuous 
positive airway pressure is effective, but adherence to treat-
ment is problematic.44 For people with insomnia, the most 
common treatments used are over-the-counter antihistamines, 
alcohol, and prescription medications such as benzodiazepine 
receptor agonists.45 These prescription hypnotics have been 
shown to have good short-term efficacy46 and good durability 
over time frames of up to 12 months,47,48 but clinical outcomes 
do not persist after treatment discontinuation, and issues 
such as rebound insomnia, dependence, abuse potential and 
respiratory depression49,50 make providers and patients hesi-
tant to use them. Cognitive behavioral therapy for insomnia 
is effective,51 but it is initially time-intensive and costly, and 
not all patients are willing or able to engage in this form of 
psychotherapy. Research identifying other treatment options 
for the general population with poor sleep quality may have 
an added benefit of improving medication adherence. 
Limitations of this study include possible selection bias, 
as the data were taken from a prospective cohort study 
in which patients were selected for variability in daytime 
sleepiness and cognitive function. In addition, as a group, 
these patients were younger and better educated than some 
community samples of HF patients. Future research is 
needed to test these results in more general populations. 
Because the analyses were exploratory, further research is 
needed to confirm these results. Further research is needed 
to investigate longitudinally both the effects of prior risk 
factors on adherence and of that adherence on subsequent 
risk factors. Adherence was measured with MEMS for a 
single HF medication. There is no guarantee that a dose of 
the medication was taken every time the MEMS device was 
opened. Moreover, adherence for medications not controlled 
by the MEMS has not been accounted for. These limitations 
are offset by several strengths. The statistical approach took 
into account patterns over time for both mean adherence 
and adherence variability, allowing a more nuanced under-
standing of medication adherence than prior studies. Other 
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strengths include the prospective design and the objective 
measurement of medication adherence. 
In conclusion, medication adherence is a continuing 
problem for which solutions are urgently needed. In this 
study, we identified three pairs of variables associated with 
nonadherence. Together, these three pairs suggest that clini-
cians caring for HF patients who are of older age, those with 
multiple comorbid conditions and taking numerous medica-
tions, and those who are newly diagnosed should anticipate 
problems with medication adherence and discuss ways to 
assist patients to avoid adherence problems. Asking patients 
about their sleep quality should be a routine element of all 
clinical encounters.52 Future research is needed to identify 
interventions that adequately address these predictors of 
nonadherence. 
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